Skip to main content
. 2018 Aug 27;13(8):e0202563. doi: 10.1371/journal.pone.0202563

Fig 3. Differences versus placebo in efficacy and safety outcomes.

Fig 3

Note: HbA1c, glycated hemoglobin; FPG, fasting plasma glucose; SGLT-2i, sodium-glucose co-transporter-2 inhibitor; DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1RA, glucagon-like peptide-1 receptor agonist; TZD, thiazolidinedione; Met, metformin; AGI, α-glucosidase inhibitor; Basal, basal (long-acting) insulin.